Personalized T cell therapy for glioblastoma using engineered nanoparticles
Official title: Engineered Glioblastoma-specific T cells using Immunostimulatory Photothermal Nanoparticles
Funded at Immunoblue, LLC · NIH-11002528 · Data updated 2026-11-12
This study is working on a new way to treat glioblastoma by using your own immune cells to better fight the tumor, with the hope that this personalized approach will help improve your treatment after surgery.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Immunoblue, LLC NIH-funded |
| Lab location | 1 site (Bethesda, United States) |
| Project start | September 3, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $399,669 |
| NIH project number | 1R41CA287488-01A1 |
| Project ID | NIH-11002528 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma who are undergoing standard-of-care surgery.
✕Less likely to help
Patients with other types of brain tumors or those who are not candidates for surgery may not benefit from this research.
What this research studies
This research aims to develop a personalized treatment for glioblastoma, the most common type of brain tumor, by creating T cells that specifically target the tumor. The approach involves using photothermal nanoparticles to heat and kill glioblastoma cells, which releases unique antigens. These antigens are then used to stimulate the patient's own immune cells, specifically T cells, to recognize and attack the tumor more effectively. The T cells are expanded in the lab and infused back into the patient after surgery, potentially improving treatment outcomes.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for glioblastoma patients, potentially improving survival rates and quality of life.
How similar studies have gone: While the approach of using engineered T cells and photothermal therapy is innovative, similar strategies in targeting tumors have shown promise in other cancers, suggesting potential for success.
Where this research is happening
-
Immunoblue, LLC
Bethesda, United States Active
Researchers
- Principal investigator: Sweeney, Elizabeth E — Immunoblue, LLC
- Study coordinator: Sweeney, Elizabeth E
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.